title: L-carnitine and cancer cachexia. II. Effects of lipid emulsion used             in total parenteral nutrition on parameters of hemostasis and inflammatory state             in L-carnitine deficiency in myocytes.
abstract: Cancer cachexia (CC), a progressive loss of body mass, leads to malnutrition and deficiencies of essential substances including polyunsaturated fatty acids (PUFAs) and L-carnitine (LC). The availability of these 2 compounds determines the rate of eicosanoid synthesis, which modulates inflammatory processes and hemostasis. We compared the effects of administration of emulsions containing long chain triglycerides (LCTs) relative to a 50:50 mix of medium chain triglycerides (MCTs) with LCTs on hemostasis and inflammatory reactions in patients with CC. The study was conducted on 50 patients with CC (23 women, 27 men) aged 66 ± 11 years with a mean loss in body weight of 21 ± 9% in the previous 6 months. Twenty patients received MCTs/LCTs while 30 received LCTs. Total parenteral nutrition (TPN) was administered using the 'all in one' method (25 kcal/kg/day, protein 1.2 g/kg/day). Selected parameters of coagulation and inflammatory state were evaluated on days 1, 5, 7 and 11 of TPN. Initial concentrations of D-dimers, fibrinogen, plasminogen activator inhibitor type 1 (PAI-1), fibronectin, CRP and IL-6 significantly exceeded the upper limit of the reference values. After 10 days of TPN, we detected significant differences in inflammatory state and hemostasis. Immunological state and hemostasis varied depending on the type of fat emulsion administered. The most likely reasons are the 2-fold higher concentrations of PUFAs in LCTs relative to MCTs/LCTs and a deficiency of LC in skeletal muscles. Both of these factors may contribute to the observed increase in the rate of eicosanoid synthesis.
authors.affiliation: Department of Surgical Oncology, Gdynia Oncology Centre, PCK's Maritime Hospital, Gdynia, Poland. jaszefel@mp.pl
authors.forename: Jarosław
authors.initials: J
authors.lastname: Szefel
authors.forename: Wiesław Janusz
authors.initials: WJ
authors.lastname: Kruszewski
authors.forename: Maciej
authors.initials: M
authors.lastname: Ciesielski
authors.forename: Mariusz
authors.initials: M
authors.lastname: Szajewski
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Kawecki
authors.forename: Jerzy
authors.initials: J
authors.lastname: Jankun
authors.forename: Wiesława
authors.initials: W
authors.lastname: Lysiak-Szydłowska
mesh_terms: D000368:Aged; D015992:Body Mass Index; D002100:Cachexia / Q000097:blood / Q000209:etiology / Q000628:therapy*; D002331:Carnitine / Q000172:deficiency*; D005217:Fat Emulsions, Intravenous / Q000008:administration & dosage*; D005260:Female; D006487:Hemostasis; D006801:Humans; D007249:Inflammation / Q000628:therapy; D008297:Male; D008875:Middle Aged; D032342:Muscle Cells / Q000378:metabolism* / Q000473:pathology; D018482:Muscle, Skeletal / Q000378:metabolism* / Q000473:pathology; D009369:Neoplasms / Q000097:blood / Q000150:complications / Q000628:therapy*; D012016:Reference Values; D016896:Treatment Outcome; D014280:Triglycerides / Q000008:administration & dosage*
chemical_list: D005217:Fat Emulsions, Intravenous; D014280:Triglycerides; D002331:Carnitine